January 2026 Research Update

Across several real-world infant studies, earlier start of alglucosidase alfa (an enzyme replacement therapy) lined up with better heart measurements over time, and many children achieved important milestones like walking. At the same time, the month adds a clearer reminder that the immune response to the enzyme (antibodies) can still be a major factor, including in some children who are not usually considered highest risk. Together, these reports reinforce a simple picture: starting very early supports stronger heart improvement, but long-term outcomes also depend on how each child responds immunologically. [1] [2] [3]

The strongest consistent signal this month was in the heart: infants who began alglucosidase alfa by 1 month of age had faster improvement toward normal heart muscle thickness and related heart ultrasound measures than those who started later. The registry analysis also found that each month of delay was linked to worse heart measurements and more abnormal findings on heart testing, although the early-treated group was small. For families, this helps explain why timing is studied so closely in infantile-onset Pompe disease, especially for protecting the heart. [1]

Two separate infant cohorts followed children who started alglucosidase alfa very early and commonly used immune tolerance induction (approaches meant to reduce anti-drug antibodies). In the US cohort treated within 4 weeks of birth, most children were alive at follow-up and described as walking, eating by mouth, and not needing invasive ventilation while receiving higher weekly dosing than standard schedules. In the Italian cohort, heart thickening normalized in all patients, and most achieved walking, but some children still died or became ventilator-dependent over long follow-up, showing that outcomes can still vary even with modern care. [2] [3]

Immune response remained a key theme, not just the enzyme dose. In the Italian group, many developed anti-drug antibodies and some reached very high antibody levels, while immune tolerance induction and long-term sirolimus were used in many patients. In the US cohort, all CRIM-negative infants who received immune tolerance induction became immune tolerant, but high sustained antibodies still occurred in a few CRIM-positive children, and one child who developed high antibodies without immune tolerance induction had a severe course. [3] [2]

This month strengthens the idea that, in infants, earlier treatment is closely tied to faster heart recovery, which is one of the biggest early threats in infantile-onset Pompe disease. It also clarifies that antibody monitoring and immune management remain important parts of research and care, because high antibody levels can still happen even in some CRIM-positive children. These are retrospective reports, so they cannot prove cause and effect, and the early-treatment groups were sometimes small, but they add useful real-world detail about what tends to go well and what can still go wrong. [1] [2] [3]

This month added new pieces to the ongoing search for practical ways to track Pompe disease beyond symptoms alone, using blood tests and imaging. For infantile-onset Pompe disease, one study reported that a blood marker called GFAP tracked with white matter changes on brain MRI and separated more severe from less severe CNS involvement better than another common nerve marker. For late-onset Pompe disease, a multicenter study found that quantitative thigh muscle imaging (especially muscle fat fraction in specific muscles) matched functional severity well and could pick up early structural changes. [4] [5]

For brain involvement in infantile-onset Pompe disease, plasma GFAP (a protein released by support cells in the brain) was higher in infantile-onset groups than in controls, and it closely matched the amount of white matter change seen on MRI. GFAP also did better than NfL (a nerve injury marker) at distinguishing infantile-onset Pompe disease from controls and at separating severe from attenuated infantile-onset cases in this dataset. This suggests a possible future blood test that could reflect brain changes without needing an MRI every time, but it still needs confirmation in larger, carefully designed studies. [4]

For late-onset Pompe disease, quantitative thigh MRI measures of muscle fat replacement were strongly linked to how affected a person was on clinical scales. Fat fraction in the adductor magnus muscle, and the ratio comparing adductor magnus to rectus femoris, most clearly separated early-stage from symptomatic disease, while the water-based signal was less informative. This supports the idea that muscle imaging could become a more sensitive way to track progression over time, but the study was cross-sectional, so it cannot yet show how well these measures predict future change for an individual. [5]

These studies mainly matter as progress toward better monitoring tools, rather than changes that immediately alter treatment decisions. If GFAP and quantitative MRI measures hold up in larger and longer studies, they could help families and researchers follow disease impact more directly, including brain involvement in infantile-onset Pompe disease and early muscle changes in late-onset disease. Important uncertainties remain, including how these tests perform across ages, how stable they are over time, and how well they track with day-to-day function for one person. [4] [5]

The rest of the month combined practical care reports with early-stage research that explores future directions. Case reports highlighted two very different real-world issues: a rapid heart response with avalglucosidase alfa in one infant, and a way to continue alglucosidase alfa after hypersensitivity reactions in another infant. A national expert consensus described what follow-up testing could look like when a health system tries to standardize Pompe monitoring. Laboratory and animal studies explored how GAA problems affect the body and how new gene therapy designs might better deliver GAA in muscle, but these do not yet tell us what will happen in patients. [6] [7] [8] [9] [10] [11] [12] [13]

In single-patient reports, one infant given first-line avalglucosidase alfa had heart thickening improve quickly and stay in a normal range through 36 months of follow-up. Another infant on alglucosidase alfa developed infusion hypersensitivity with hives, and after two unsuccessful attempts, a more gradual multi-step desensitization approach allowed full dosing without recurrent reactions in later infusions. These cases do not prove what will happen for others, but they show the range of treatment journeys that families sometimes face. [6] [7]

A separate case report focused on diagnosis in a setting with limited access to cardiac testing and enzyme therapy, showing that a dried blood spot enzyme test plus genetic testing identified a specific disease-causing GAA variant and enabled carrier testing in parents. In parallel, the Austrian Pompe Outcome Consensus listed a minimum and optional set of follow-up assessments across mobility, breathing, imaging, labs, nutrition, and quality of life, aiming for more consistent monitoring. For families, these papers underline that diagnosis and follow-up can look very different across countries, and that standardization efforts are still evolving. [13] [8]

Early research explored both new models and potential future treatments. In Gaa-knockout mice, an AAV9 gene therapy design that added a muscle enhancer produced higher GAA activity in heart and limb muscles and improved muscle strength in male mice, with weaker responses in females and no anti-GAA antibodies detected in this model. In patient-derived cells from GMPPB deficiency (a different genetic condition), researchers found reduced GAA activity due to impaired processing and targeting, and recombinant human GAA corrected the cell changes and cleared glycogen, highlighting that GAA-related lysosomal problems can also appear secondarily in other disorders. [9] [11]

Other exploratory work aimed to map biology rather than test a therapy. A fruit-fly model with brain-specific lowering of the Pompe gene counterpart shortened male lifespan but had little effect when the gene was lowered in the gut, suggesting the nervous system may be especially important in that model. A computer-based reanalysis of an existing infantile-onset Pompe dataset identified many gene-expression differences and predicted microRNAs that might regulate GAA, raising the possibility of future blood biomarkers, but these predictions need real-world testing. [10] [12]

The case reports are most relevant for understanding what can happen in individual situations, such as rapid heart improvement on avalglucosidase alfa or continuing alglucosidase alfa after a hypersensitivity reaction using a carefully stepped infusion approach. The consensus paper may matter now in places working to standardize follow-up, but it reflects expert agreement rather than direct evidence that one schedule is best. The lab and animal studies mainly matter for the future because they test ideas and tools, not patient outcomes, but they help explain where new treatments and new biomarkers might come from. [6] [7] [8] [9] [11] [10] [12] [13]